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The  aim  of our  study  was  to investigate  whether  osteoprotegerin  (OPG)  is related  to  in-hospital  major
adverse  cardiac  events  (MACE)  and  reperfusion  parameters  in patients  with  ST elevation  myocardial
infarction  (STEMI).  The  OPG/receptor  activator  of nuclear  factor-B  (RANK)/RANK  ligand  pathway  has
recently  been  associated  with  atherosclerosis.  OPG  is  a  predictor  of  cardiovascular  events  in  patients
with  acute  coronary  syndrome.  This  study  included  96  consecutive  patients  with  STEMI  undergoing
primary  percutaneous  coronary  intervention  (PCI).  Two  groups  with  equal  number  of  patients  were
formed  according  to  median  OPG  level.  The  association  of OPG  levels  on admission  with  post-procedural
reperfusion  parameters,  and in-hospital  MACE  were  investigated.  Patients  with  higher  OPG  levels  dis-
played  higher  neutrophil/lymphocyte  ratio,  admission  troponin,  admission  glucose,  and  high-sensitive
C-reactive  protein.  Higher  OPG  levels  were  associated  with  increased  thrombolysis  in  myocardial  infarc-
tion (TIMI)  risk  score,  TIMI risk  index,  pain  to balloon  time,  need  for inotropic  support,  shock,  and  MACE,
mainly  driven  by death.  Reperfusion  parameters  were  not  different  between  the  two  groups.  TIMI  risk
score, TIMI  risk  index,  myocardial  blush  grade,  estimated  glomerular  ﬁltration  rate  (eGFR),  number  of
obstructed  vessels,  and OPG  signiﬁcantly  predicted  adverse  cardiac  events.  Multiple  logistic  regression
analysis  revealed  OPG  as  an independent  predictor  of  MACE  as  well  as  eGFR,  number  of obstructed  ves-
sels, and  corrected  TIMI  frame  count.  OPG,  a bidirectional  molecule  displaying  both  atheroprotective  and
pro-atherosclerotic  properties,  is currently  known  as  a  marker  of inﬂammation  and  a  predictor  of  car-
diovascular  mortality.  The  present  study,  for  the  ﬁrst  time,  demonstrated  that  an  increased  OPG  level  is
related to in-hospital  adverse  cardiovascular  events  after  primary  PCI  in  patients  with  STEMI.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Osteoprotegerin (OPG), a glycoprotein and a member of the
umor necrosis factor (TNF) receptor superfamily, forms the molec-
lar link between skeletal, immune, and vascular systems [1,2].
PG prevents osteoclast-mediated bone resorption, by binding
he receptor activator of nuclear factor-B ligand (RANKL), act-
ng as a decoy receptor to competitively inhibit the interaction of
ANKL with its receptor, receptor activator of nuclear factor-B
RANK) [3].  In addition, OPG demonstrated anti-apoptotic activ-
ty by binding to another receptor of the TNF family, TNF-related
∗ Corresponding author at: Rize University, Faculty of Medicine, Department of
ardiology, 53100 Rize, Turkey. Tel.: +90 464 212 30 09; fax: +90 464 212 30 15.
E-mail address: emredur@hotmail.com (M.E. Durakog˘lugil).
914-5087/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jjcc.2012.05.010apoptosis-inducing ligand (TRAIL) [4].  Recently, OPG has gained
considerable interest in the cardiovascular discipline due to its
association with inﬂammation and atherosclerosis. Increased OPG
levels have been associated with endothelial dysfunction [5],  coro-
nary calcium score [6],  presence and severity of coronary artery dis-
ease (CAD) [7],  peripheral vascular disease [8],  and cerebrovascular
disease [9].
ST elevation myocardial infarction (STEMI) is a major cause of
cardiovascular mortality and morbidity. Despite advances in emer-
gent revascularization including primary percutaneous coronary
intervention (PCI), acute heart failure, shock, and mechanical com-
plications are still encountered as major problems during hospital
care [10,11]. The prognosis of STEMI is quite variable depending on
a number of clinical, echocardiographic, and biochemical markers.
Thus, identiﬁcation of new molecules for risk stratiﬁcation to select
patients at high risk for adverse clinical end-points is important. In
vier Ltd. All rights reserved.
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ddition, these molecules may  help to reveal new aspects in the
athophysiology of acute and chronic vascular events.
Preliminary studies investigating the relationship between
TEMI and OPG documented increased OPG levels in patients with
TEMI compared to patients with stable CAD and normal con-
rols [12]. Prominent immunostaining of OPG/RANK/RANKL were
emonstrated within the thrombus material, aspirated during pri-
ary PCI for acute STEMI [13]. Although OPG is a strong predictor
f mortality and heart failure (HF) in patients with acute coro-
ary syndrome (ACS) [14], whether OPG is related to in-hospital
ajor adverse cardiac events (MACE) and reperfusion parame-
ers in patients with STEMI has not been clariﬁed until now. We
ntended to investigate OPG levels in patients with STEMI and eval-
ate its relationship with reperfusion parameters and in-hospital
ACE.
ethods
This study was conducted prospectively, in the cardiology clinic
t Rize Education and Research Hospital, Rize, Turkey. Ninety six
atients with STEMI with no history of previous CAD, who  under-
ent primary PCI at our institution between May  2011 and January
012, were enrolled consecutively. The diagnosis of acute STEMI
as made as previously described [15]. The diagnosis of acute
TEMI was also conﬁrmed by demonstrating the culprit lesion by
oronary angiography. Informed consent was obtained from all
atients prior to the study. The study was performed in accor-
ance with the principles stated in the Declaration of Helsinki and
pproved by the Local Ethics Committee.
Clinical characteristics, which consisted of multiple descriptors
rom each patient’s history and physical examination, were col-
ected by physicians from cardiology clinics of each patient and
ere stored in the database of the coronary angiography labo-
atory. We  recorded the baseline characteristics, which include
ypertension, diabetes mellitus, smoking status, family history of
remature CAD and lipid parameters. Killip score [16], thrombol-
sis in myocardial infarction (TIMI) risk index [17], and TIMI risk
core [18] was also calculated and used for risk stratiﬁcation.
Patients with signiﬁcant organic valvular heart disease, known
istory of CAD or prior MI,  malignancy, collagen vascular disease,
hronic kidney and hepatic failure, pulmonary embolism, and sep-
is were excluded from the study. The exclusion criteria were
elected to avoid confounding factors other than STEMI origin and
ocation.
A 12-lead surface electrocardiogram (ECG) was obtained from
ll patients in the supine position immediately after their admis-
ion to the emergency care unit (ECU). The 12-lead ECG (Cardiofax
 ECG-1250K, ﬁlter range 0.5–150 Hz, AC ﬁlter 60 Hz, 25 mm/s,
0 mm/mV;  Nihon Kohden, Tokyo, Japan) was analyzed by two
ndependent clinicians who were blind to study design and data.
 repeat ECG was obtained 60 min  after primary PCI. A special ruler
as used to measure the difference (in mm)  between isoelectric
ine and ST-segment elevation at 20 ms  after the J-point. Jeopar-
ized myocardium was determined by the sum of ST elevations
in mm)  on each ST-elevated derivation on pre- and post-PCI ECGs
total ST elevation score). Percentage of total ST resolution was cal-
ulated by the following formula: (sum of ST elevations on pre-PCI
CG) − (sum of ST elevations on post-PCI ECG)/(sum of ST elevations
n pre-PCI ECG) × 100.
Cardiac biomarkers levels including creatine kinase (CK), CK-MB
raction (CK-MB), troponin-I, and inﬂammatory markers including
eukocytes were measured at our emergency department and used
n the analyses as admission values. The lipid samples were eval-
ated after fasting for at least 8 h. Glucose, creatinine, and lipid
roﬁle were determined by the standard methods. White bloodology 60 (2012) 355–360
cell (WBC, leukocyte) counts were obtained from an automated cell
counter (Coulter Gen-S, Coulter Corp., Miami, FL, USA). Estimated
glomerular ﬁltration rate (eGFR) was calculated by Cockroft–Gault
formula [19].
Blood samples for OPG were drawn prior to primary PCI and
serum, isolated by centrifugation within 1 h at 2500 × g for 10 min,
and stored at −80 ◦C. Serum levels of OPG were quantiﬁed by
enzyme-linked immunosorbent assay (ELISA) using commercially
available matched antibodies (eBioscience, San Diego, CA, USA).
The intra-assay and inter-assay coefﬁcients of variation (CV) were
7.0% and 8.0%, respectively. The sensitivity was  calculated to be
2.5 pg/mL.
Admission serum specimens for high sensitivity C-reactive pro-
tein (hsCRP) were frozen at −20 ◦C before analysis. Serum levels
of hsCRP were determined by an immunoturbidimetric method
performed on the Abbott auto-analyzer (Architect C1600, Abbott,
Abbott Park, IL, USA).
All of the patients received 300 mg  aspirin and a loading dose
of 600 mg  clopidogrel prior to the procedure. After sheath inser-
tion via femoral approach, an intravenous bolus of unfractionated
heparin at a dose of 70 IU/kg was  administered. Coronary stenting
directly, or after balloon angioplasty, was performed where eligible.
Glycoprotein IIb–IIIa inhibitor (tiroﬁban) was administered at the
preference of the operator. After the procedure, all patients were
treated according to the current recommendations by clinicians
blinded to OPG concentrations and followed-up in the coronary
care unit and cardiology clinics until discharge. MACE were deﬁned
as recurrent myocardial infarction, stroke, decompensated HF, and
cardiac death. In hospital re-infarction was deﬁned as recurrent
chest pain lasting more than 30 min, associated with new Q waves
or recurrent ST-segment elevation ≥0.1 mV in at least two  contigu-
ous leads and an increase in CK-MB levels to at least twice the upper
limit of normal value and/or more than 50% above the previous
value after the index procedure.
Preprocedural and postprocedural TIMI ﬂow grade [20], cor-
rected TIMI frame count (TFC) [21], and myocardial blush grade
[22] were assessed by two cardiologists blinded to patient data.
Statistical analyses
Continuous variables were given as mean ± SD; categorical vari-
ables were deﬁned as percentage. Data were tested for normal
distribution using the Kolmogorov–Smirnov test. The Student’s t-
test was  used for the univariate analysis of normally distributed
continuous numerical variables and Mann–Whitney U-test was
used for non-normally distributed numerical variables, and the
2-test for the categorical variables. Spearman’s rank correlation
coefﬁcient was  used to analyze the relationship between numer-
ical and ordinal variables. For presentation of data, two groups
were formed as above and below the median OPG  level. More-
over, additional groups were made up according to the presence
or absence of MACE. Logistic regression analysis was used for mul-
tivariate analysis of independent variables. All tests of signiﬁcance
were two-tailed. Statistical signiﬁcance was deﬁned as p < 0.05. The
Statistical Program for Social Sciences (SPSS for windows 15, Inc.,
Chicago, IL, USA) was used for all statistical calculations.
Results
The baseline clinical characteristics are presented in Table 1. The
study population consisted of 96 patients with STEMI who under-
went primary PCI. Blood samples were obtained within 30 min
after admission, before administration of any medication. The mean
plasma OPG level was 109 ± 134 pg/mL, with a median value of
70 pg/mL. The baseline clinical characteristics of the subgroups,
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Table  1
Baseline demographics and clinical characteristics.
Characteristic (median
OPG: 70 pg/mL) N (96)
OPG < median
(48)
OPG ≥ median
(48)
p-Value
Age (yrs) 53 ± 29 63 ± 34 <0.001
BMI  (kg/m2) 27.6 ± 4.1 27.8 ± 4.1 NS
Gender (male) 85% 79% NS
Hypertension 35% 35% NS
Diabetes mellitus 8% 29% 0.009
Smoking 69% 67% NS
Hyperlipidemia 19% 17% NS
Family history of
premature CAD
15% 4% 0.080
Heart rate (bpm) 82 ± 15 82 ± 19 NS
Admission blood glucose
(mg/dl)
145 ± 62 192 ± 137 0.025a
Fasting blood glucose
(mg/dl)
119 ± 40 148 ± 77 0.023
Creatinine (mg/dl) 0.93 ± 0.29 1.03 ± 0.32 NSa
eGFR (mL/min) 105 ± 34 83 ± 28 0.001
Total cholesterol (mg/dl) 184 ± 47 182 ± 41 NS
LDL (mg/dl) 120 ± 37 120 ± 35 NS
HDL (mg/dl) 37 ± 10 39 ± 8 NS
Triglyceride (mg/dl) 133 ± 80 119 ± 72 NS
Leukocytes (103/mm3) 11 ± 3 13 ± 5 0.067
Neutrophils (103/mm3) 7 ± 3 9 ± 5 0.024a
Lymphocyte (103/mm3) 2.9 ± 1.4 2.1 ± 1.1 0.002a
Monocyte (/mm3) 0.68 ± 0.26 0.68 ± 0.35 NSa
N/L ratio 3.4 ± 3.2 5.4 ± 4.0 0.007
Hemoglobin (mg/dl) 14.4 ± 1.4 13.4 ± 1.4 0.001
Platelet count (109/L) 260 ± 57 245 ± 54 NS
CK-MB (U/L) (Adm.) 25 ± 63 50 ± 81 0.098
CK-MB (U/L) (peak) 210 ± 96 213 ± 100 NSa
Troponin I (ng/mL) (Adm.) 2.8 ± 8.2 10.1 ± 16.9 0.012
Troponin I (ng/mL) (peak) 45 ± 11 46 ± 11 NSa
C-reactive protein (mg/dl) 0.83 ± 1.23 2.1 ± 3.6 0.002a
Q wave on ECG % 61% 74% NS
Left  ventricular ejection
fraction (%)
44 ± 10 43 ± 10 NS
Medications
Aspirin 13% 21% NS
Clopidogrel 0% 4% NS
Beta  blockers 6% 17% NS
Statins 4% 13% NS
ACEI/ARB 23% 17% NS
CCB  6% 15% NS
Tiroﬁban 10% 21% NS
OAD/insulin 8% 21% NS
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor block-
ers;  Adm., admission value; BMI, body mass index; CAD, coronary artery
disease; CCB, calcium channel blocker; CK, creatinine kinase; CK-MB, creati-
nine kinase muscle/brain; ECG, electrocardiogram; eGFR, estimated glomerular
ﬁltration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N/L,
neutrophil/lymphocyte; NS, not signiﬁcant; OAD, oral anti-diabetic; OPG, osteopro-
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Table 2
Angiographic characteristics and procedural results.
Characteristic OPG < median OPG ≥ median p-Value
Pre-procedural characteristics
TIMI risk score 3.3 ± 2.7 5.4 ± 2.8 0.001
TIMI risk index 21 ± 11 31 ± 16 0.001
Pain to balloon time (min) 278 ± 234 439 ± 374 0.001a
Baseline TIMI grade 0 or 1 89% 85% NS
Thrombus score 4 or 5 96% 90% NS
Anterior MI  48% 48% NS
Total ST elevation on
admission (mm)
9.5 ± 7.3 10.4 ± 7.6 NSa
Number of obstructed vessels
≥50%
2.0 ± 0.8 2.2 ± 0.8 NSa
Post-procedural results
TIMI ﬂow grade (2, 3) 94% 90% NS
Corrected TIMI frame count 27 ± 21 30 ± 24 NSa
Myocardial blush grade (2, 3) 73% 63% NS
ST  resolution % 56 ± 52 53 ± 33 NSa
In-hospital course
MACE 8% 29% 0.009
Death 0% 13% 0.011
Re-MI 4% 10% NS
Stroke 0% 0% NS
Decompensated HF 6% 19% 0.064
Shock 0% 13% 0.011
Need for inotropic support 2% 17% 0.014
CPR  0% 19% 0.002
Atrial ﬁbrillation 6% 10% NS
Major/minor bleeding 4% 8% NS
Pre-PCI cardiac arrest 2% 13% 0.05
VT/VF 4% 8% NS
CPR, cardiopulmonary resuscitation; HF, heart failure; MACE, major adverse cardiac
event; MI,  myocardial infarction; OPG, osteoprotegerin; PCI, percutaneous coronaryegerin; PCI, percutaneous coronary intervention.
a Nonparametric variables were analyzed by Mann–Whitney U-test.
ith OPG levels higher and lower than the median, are com-
ared in Table 1. Patients with higher OPG levels were more likely
o be older, to have history of diabetes mellitus, to have lower
emoglobin levels, and eGFR. In addition, in patients with higher
PG, higher values of leukocyte count, neutrophil/lymphocyte
N/L) ratio, admission troponin, admission glucose, CRP, and hsCRP
ere also documented.
Angiographic characteristics and procedural results are detailed
n Table 2. Higher OPG levels were associated with increased
IMI risk score (p = 0.001), TIMI risk index (p = 0.001), pain to bal-
oon time (p = 0.014), need for inotropic support (p = 0.014), shock
p = 0.011), and MACE (p = 0.009), mainly driven by increased mor-
ality in this group (p = 0.011) (Fig. 1). There was a trend for
ncreased decompensated HF, although not reaching signiﬁcance.
eperfusion parameters including TIMI ﬂow grade, corrected TFC,
yocardial blush grade, and percentage of ST segment resolution
as not different between the two groups. Correlation analysisintervention; TIMI, thrombolysis in myocardial infarction; VF, ventricular ﬁbrilla-
tion; VT, ventricular tachycardia.
a Nonparametric variables were analyzed by Mann–Whitney U-test.
demonstrated that OPG related to N/L ratio (r = 0.364, p < 0.001),
and hsCRP (r = 0.337, p = 0.001) signiﬁcantly.
Female gender, plasma creatinine, glucose, hemoglobin, neu-
trophil/leukocyte count, eGFR, left ventricular ejection fraction
(LVEF), TIMI risk score, Killip score, TIMI risk index, myocar-
dial blush grade, number of obstructed vessels, corrected TFC,
and OPG signiﬁcantly predicted adverse cardiac events (Table 3).
Multiple logistic regression analysis including age, gender, eGFR,
hemoglobin, admission glucose level, N/L ratio, number of
obstructed vessels ≥50%, corrected TFC, hs-CRP, LVEF, and OPG lev-
els revealed OPG as an independent predictor of MACE (odds ratio:
1.008, 95% CI: 1.003–1.015, p = 0.016) as well as eGFR, number of
obstructed vessels, and corrected TFC (Table 4).
Discussion
We demonstrated for the ﬁrst time that increased OPG lev-
els are associated with higher in-hospital MACE in patients with
STEMI. Higher OPG concentrations also indicated increased TIMI
risk score, pain to balloon time, need for inotropic support, shock,
and hsCRP potentially delineating a high-risk group. Furthermore,
corrected TFC and myocardial blush grade did not differ signiﬁ-
cantly between the two groups, formed according to OPG levels.
Despite the lack of association with reperfusion parameters, OPG
correlated with hsCRP, N/L ratio, and remained as the strongest
independent parameter in the multivariate analysis.
Data regarding the relationship between STEMI and OPG in the
current medical literature are scarce. A previous study documented
increased OPG levels in patients with STEMI compared to patients
with CAD and normal controls [12]. Prominent immunostaining of
OPG/RANK/RANKL were demonstrated within the thrombus mate-
rial, aspirated during primary PCI for acute STEMI, implicating a
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Table 3
Relationship of major adverse cardiovascular events with prognostic parameters in
study.
Parameters Major adverse
cardiovascular events
p-Value
Absence Presence
Age (yrs) 60 ± 13 66 ± 10 0.062
BMI  (kg/m2) 27 ± 4 28 ± 6 NS
Gender (male) 87% 65% 0.023
Hypertension 34% 50% NS
Diabetes mellitus 16% 30% NS
Smoking 73% 50% NS
Hyperlipidemia 16% 20% NS
Family history of CAD 10% 5% NS
Heart rate (bpm) 80 ± 17 86 ± 21 NS
Creatinine (mg/dl) 0.9 ± 0.3 1.3 ± 0.6 0.001a
eGFR (mL/min) 98 ± 32 69 ± 31 0.001
Admission blood glucose (mg/dl) 154 ± 72 219 ± 183 0.017a
Fasting blood glucose (mg/dl) 124 ± 52 166 ± 72 0.076
Leukocytes (103/mm3) 11 ± 3 15 ± 7 0.005
Neutrophils (103/mm3) 7 ± 3 12 ± 7 0.005a
Hemoglobin (mg/dl) 14.1 ± 1.5 13.3 ± 1.8 0.06
EF% 45 ± 10 39 ± 8 0.012
Troponin I (peak) 1.6 ± 0.2 1.7 ± 0.1 NSa
HsCRP −0.3 ± 0.5 −0.1 ± 0.7 NSa
N/L ratio 3.9 ± 3.0 6.2 ± 5.4 0.079
Killip score 1.1 ± 0.3 2.1 ± 1.0 <0.001
TIMI risk score 3.8 ± 2.5 7.5 ± 3.1 <0.001
TIMI risk index 23 ± 11 40 ± 18 0.001
Osteoprotegerin (pg/mL) 85 ± 66 215 ± 257 0.002a
Total ST elevation on admission (mm)  10 ± 7 12 ± 10 NSa
ST segment resolution % 54 ± 45 60 ± 30 NSa
Corrected TIMI frame count 26 ± 19 44 ± 31 0.001a
Myocardial blush grade (2, 3) 72% 50% 0.018
Number of obstructed vessels ≥50% 2.0 ± 0.8 2.5 ± 0.8 0.012a
BMI, body mass index; CAD, coronary artery disease; EF, ejection fraction; eGFR,
estimated glomerular ﬁltration rate; HsCRP, high-sensitivity C-reactive protein; N/L,
neutrophil/lymphocyte; TIMI, thrombolysis in myocardial infarction.
a Nonparametric variables were analyzed by Mann–Whitney U-test.
Fig. 1. Kaplan–Meier survival plot documenting increased major adverse cardiac event raology 60 (2012) 355–360
potential causative role [13]. Previous studies identiﬁed OPG as an
independent predictor of HF and mortality in patients with myocar-
dial infarction complicated with HF and ACS [14,23]. Moreover,
higher OPG levels were associated with a larger infarct size after
STEMI [24].
In the present study, despite the documented association
between increased OPG levels and in-hospital MACE in patients
with STEMI, the exact cause of this relationship is still unknown.
Whether OPG has an independent active pathophysiologic effect
or is just a marker of severity has not been clariﬁed. In vitro studies
identiﬁed OPG to have anti-atherosclerotic properties by inhibiting
vascular calciﬁcation, regulating B-cell maturation, and demon-
strating anti-apoptotic activity [1,25].  However, regardless of the
convincing evidence for antiatherogenic effects in animal models,
OPG seems to be associated with CAD and a marker of mortal-
ity in human studies [9,26].  There may  be several explanations
for this association. Endothelial and vascular smooth muscle cells
secrete OPG in response to TNF- [27]. Previous studies reported
increased expression of RANK in monocytes, RANKL mRNA in
T-cells in patients with unstable angina, and OPG/RANK/RANKL
speciﬁcally in the atherosclerotic plaques. Moreover, supported
with the evidence that RANKL increases matrix metalloproteinase
(MMP)  activity, OPG/RANK/RANKL axis seems to be a crucial fac-
tor in unstable coronary syndromes [13]. Therefore, OPG alone
may  not be effective in neutralizing RANK/RANKL interaction, par-
ticularly at high RANKL concentrations. In addition, binding of
OPG may  possibly hinder clearance of RANKL which increases
RANKL actions. Thus, higher OPG concentration, corresponding
to a low OPG/RANKL ratio, could indicate overall activity in the
OPG/RANK/RANKL system.
In contrast to protective properties, higher OPG levels are asso-
ciated with increased endothelial cell adhesion and migration of
inﬂammatory cells [28], enhanced MMP-mediated matrix degrada-
tion [13], diminished endothelial nitric oxide synthase activity [29],
and blocked potential anti-inﬂammatory activity of TRAIL [30];
te in patients with higher osteoprotegerin (OPG) concentrations; Cum, cumulative.
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Table  4
Multivariate logistic regression analysis: predictors for major adverse cardiovascular events.
Predictors OR 95% CI p-value* OR 95% CI p-Valuea
Major adverse cardiovascular events
Age (yrs) 0.996 0.916–1.082 0.918
Gender (male) 0.384 0.041–3.575 0.400
Admission blood glucose (mg/dl) 0.999 0.991–1.007 0.868
Hemoglobin (mg/dl) 1.549 0.713–3.365 0.269
eGFR (mL/min) 0.950 0.905–0.997 0.037 0.971 0.944–0.999 0.042
N/L  ratio 0.960 0.800–1.153 0.663
C-reactive protein (mg/dl) 1.278 0.957–1.707 0.096
Osteoprotegerin (pg/mL) 1.011 1.001–1.021 0.034 1.008 1.003–1.015 0.016
LVEF  (%) 0.935 0.850–1.030 0.173
Number of obstructed vessels ≥50% 2.974 0.928–9.536 0.067 2.906 1.051–8.037 0.040
Corrected TIMI frame count 1.039 1.006–1.073 0.021 1.039 1.011–1.069 0.006
Constant 0.009 – 0.497 0.020 – 0.041
R2 0.593 0.516
CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate; LVEF, left ventricular ejection fraction; N/L, neutrophil/lymphocyte; OR, odds ratio; TIMI, thrombolysis in
myocardial infarction.
a Logistic regression analysis with Backward: LR method was used for multivariate analysis of independent causative variables including age, gender, eGFR, hemoglobin,
admission glucose level, N/L ratio, number of obstructed vessels ≥50%, corrected TIMI frame count, high-sensitivity C-reactive protein, LVEF, and osteoprotegerin levels; and
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ll in favor of an advanced atherosclerotic process. Consequently,
ncreased OPG concentration may  be an ineffective compensatory
echanism in order to heal vascular insult, and a marker of inﬂam-
ation in cardiovascular disease. Similarly, hsCRP and N/L ratio was
ncreased in patients with higher OPG levels and correlated to OPG
n our study.
A recent study, investigating the relationship between
icrovascular perfusion and higher OPG levels, revealed increased
ngiographic no-reﬂow, microvascular obstruction, and microcir-
ulatory resistance after primary PCI in patients with STEMI [31].
e could not demonstrate a signiﬁcant association between OPG
nd reperfusion parameters in our study. However, we  did not
easure index of microcirculatory resistance, a better marker of
icrovascular obstruction, as in the referenced study.
Our study includes a small group of patients, which could
ave diminished the statistical signiﬁcance of relationship between
eperfusion and acute decompensated HF. In addition, we could not
easure RANKL level, however OPG may  be a more reliable and
table marker of OPG/RANKL/RANK activity [2].
OPG, a multifaceted molecule displaying both atheroprotective
nd pro-atherosclerotic properties, is a marker of inﬂammation
nd a predictor of cardiovascular mortality. We,  for the ﬁrst time,
emonstrated that increased OPG level is related to in-hospital
dverse cardiovascular events after primary PCI in patients with
TEMI.
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